TIDMSNG
RNS Number : 4657N
Synairgen plc
30 September 2021
Synairgen plc
('Synairgen' or the 'Company')
Non-Executive Director Appointment
Southampton, UK - 30 September 2021: Synairgen plc (LSE: SNG),
the drug discovery, development and commercialisation company, is
pleased to announce the appointment of Theodora Harold as an
independent Non-Executive Director of the Company and Chair of the
Audit Committee with immediate effect.
Theodora has over 20 years' experience in the biotech sector and
is currently CEO of Crescendo Biologics Ltd. She was previously
part of the founding management teams of both PsiOxus Therapeutics
Ltd and Mission Therapeutics Ltd. Theodora has previous
non-executive director experience at Chronos Therapeutics Ltd.
Theodora is also a Chartered Accountant having qualified at
PricewaterhouseCoopers.
Simon Shaw, Chair of Synairgen, commented: "I am delighted to
have Theodora joining the Board at this pivotal transition point
for Synairgen. Her breadth and depth of experience brings a welcome
new perspective to the Board and her expertise in the life sciences
and biotech industries will be of great value to Synairgen
particularly as we move into a new phase of rapid change with our
Phase III trial for SNG001 (inhaled interferon beta) nearing
completion."
Theodora Harold, newly appointed Non-Executive Director and
Chair of the Audit Committee added: "Building on the
ground-breaking work of Professor Sir Stephen Holgate and his team
at University of Southampton, Synairgen is at an important stage in
its growth as it looks to expand access of this innovative inhaled
interferon beta treatment to patients, particularly those severely
ill with COVID-19. This is an exciting time to join the Synairgen
team, and I look forward to working with Simon and the Board in
pursuing a successful future for the Company. "
As required under Schedule Two, paragraph (g) of the AIM Rules
for Companies, further disclosures on Ms Harold are as follows:
Ms Theodora Caroline Harold, aged 47, has held the following
directorships and/or partnerships in the past five years:
Current directorships and/or partnerships:
-- Crescendo Biologics Limited
Past directorships and/or partnerships:
-- Chronos Therapeutics Ltd
-- Dreadnought Ltd
-- Cambridge Consultancy Services Ltd
-- Orlixus Ltd
Ms Harold holds no ordinary shares in the Company.
There is no further information on Ms Harold required to be
disclosed under Schedule Two, paragraph (g) of the AIM Rules for
Companies.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (UK Financial Media and
Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted
broad-spectrum antiviral treatment delivered directly into the
lungs. Granted Fast Track status from the US Food and Drug
Administration (FDA) and deemed an Urgent Public Health study by
the UK's National Institute for Health Research (NIHR), Synairgen's
Phase III clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase II trial in
hospitalised COVID-19 patients, SNG001 demonstrated a greater than
twofold chance of recovery to 'no limitation of activities' versus
placebo.
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUGUBUPGPPB
(END) Dow Jones Newswires
September 30, 2021 02:01 ET (06:01 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024